Lori L Davis

Summary

Country: USA

Publications

  1. ncbi Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population
    Lori L Davis
    Veterans Affairs Medical Center, Tuscaloosa, AL 35404, USA
    J Clin Psychopharmacol 28:84-8. 2008
  2. ncbi Valproate therapy for chronic, combat-induced posttraumatic stress disorder
    Frederick Petty
    J Clin Psychopharmacol 22:100-1. 2002
  3. ncbi Divalproex sodium in the treatment of adults with bipolar disorder
    Lori L Davis
    University of Alabama at Birmingham, Birmingham, AL, USA
    Expert Rev Neurother 4:349-62. 2004
  4. ncbi A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex
    Lori L Davis
    Research and Development Department, Tuscaloosa VA Medical Center, Tuscaloosa, AL 35404, USA
    J Clin Psychiatry 68:1546-51. 2007
  5. ncbi A randomized controlled trial of supported employment among veterans with posttraumatic stress disorder
    Lori L Davis
    Research and Development Service, Tuscaloosa Veterans Affairs Medical Center, 3701 Loop Road East, Tuscaloosa, AL 35404, USA
    Psychiatr Serv 63:464-70. 2012
  6. ncbi Clinical and pharmacoeconomic evaluation of switch to olanzapine in veterans with schizophrenia or schizoaffective disorder
    Lori L Davis
    University of Alabama School of Medicine, Birmingham, AL, USA
    Psychopharmacol Bull 41:85-98. 2008
  7. ncbi Major depression and comorbid substance use disorders
    Lori Davis
    VA Medical Center, Research and Development, Tuscaloosa, AL 35404, USA
    Curr Opin Psychiatry 21:14-8. 2008
  8. ncbi Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort
    Lori L Davis
    Department of Veterans Affairs VA Medical Center, Tuscaloosa, Ala 35404, USA
    J Clin Psychiatry 68:1931-8. 2007
  9. ncbi Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes
    Lori L Davis
    VA Medical Center, 3701 Loop Road E, Tuscaloosa, AL 35404, USA
    Drug Alcohol Depend 107:161-70. 2010
  10. ncbi Long-term pharmacotherapy for post-traumatic stress disorder
    Lori L Davis
    VA Medical Center, Tuscaloosa, Alabama 35404, USA
    CNS Drugs 20:465-76. 2006

Detail Information

Publications25

  1. ncbi Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population
    Lori L Davis
    Veterans Affairs Medical Center, Tuscaloosa, AL 35404, USA
    J Clin Psychopharmacol 28:84-8. 2008
    ..To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster...
  2. ncbi Valproate therapy for chronic, combat-induced posttraumatic stress disorder
    Frederick Petty
    J Clin Psychopharmacol 22:100-1. 2002
  3. ncbi Divalproex sodium in the treatment of adults with bipolar disorder
    Lori L Davis
    University of Alabama at Birmingham, Birmingham, AL, USA
    Expert Rev Neurother 4:349-62. 2004
    ..The use of divalproex in the treatment of bipolar and other related psychiatric disorders is reviewed...
  4. ncbi A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex
    Lori L Davis
    Research and Development Department, Tuscaloosa VA Medical Center, Tuscaloosa, AL 35404, USA
    J Clin Psychiatry 68:1546-51. 2007
    ..To determine the optimal strategy for converting stable bipolar patients from twice-daily divalproex delayed release (DR) to once-daily divalproex extended release (ER)...
  5. ncbi A randomized controlled trial of supported employment among veterans with posttraumatic stress disorder
    Lori L Davis
    Research and Development Service, Tuscaloosa Veterans Affairs Medical Center, 3701 Loop Road East, Tuscaloosa, AL 35404, USA
    Psychiatr Serv 63:464-70. 2012
    ..This study is the first to examine the outcome of evidence-based supported employment for veterans with PTSD...
  6. ncbi Clinical and pharmacoeconomic evaluation of switch to olanzapine in veterans with schizophrenia or schizoaffective disorder
    Lori L Davis
    University of Alabama School of Medicine, Birmingham, AL, USA
    Psychopharmacol Bull 41:85-98. 2008
    ..Second-generation atypical antipsychotics improve the outcome of patients with schizophrenia, although studies of their cost efficacy in comparison to first-generation conventional antipsychotics have yielded mixed results...
  7. ncbi Major depression and comorbid substance use disorders
    Lori Davis
    VA Medical Center, Research and Development, Tuscaloosa, AL 35404, USA
    Curr Opin Psychiatry 21:14-8. 2008
    ..The review also addresses the possible explanations cited in the literature as to why these two disorders tend to co-occur and the implications of the comorbidity of these illnesses on treatment...
  8. ncbi Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort
    Lori L Davis
    Department of Veterans Affairs VA Medical Center, Tuscaloosa, Ala 35404, USA
    J Clin Psychiatry 68:1931-8. 2007
    ....
  9. ncbi Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes
    Lori L Davis
    VA Medical Center, 3701 Loop Road E, Tuscaloosa, AL 35404, USA
    Drug Alcohol Depend 107:161-70. 2010
    ..More intensive treatment is most likely needed for MDD patients with both drug and alcohol use disorders...
  10. ncbi Long-term pharmacotherapy for post-traumatic stress disorder
    Lori L Davis
    VA Medical Center, Tuscaloosa, Alabama 35404, USA
    CNS Drugs 20:465-76. 2006
    ..The effect of other agents (atypical antipsychotics, AEDs and other psychotropic medications) requires further controlled study...
  11. ncbi Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort
    Lori L Davis
    VA Medical Center, Tuscaloosa, AL 35404, USA
    Am J Addict 15:278-85. 2006
    ..048 to <0.0001). They were also less likely to be Hispanic and endorse general medical comorbidities (p = 0.006 and 0.002, respectively)...
  12. ncbi Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial
    Lori L Davis
    VA Medical Center, Tuscaloosa, Alabama 35404, United States
    Depress Anxiety 29:111-22. 2012
    ..These patients are often excluded from clinical trials, resulting in a significant knowledge gap regarding optimal pharmacotherapy for the treatment of MDD with concurrent SUD...
  13. ncbi Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort
    Lori L Davis
    VA Medical Center, Tuscaloosa, AL 35404, USA
    Compr Psychiatry 46:81-9. 2005
    ..In conclusion, gender, marital status, age of onset of major depression, functional impairment, and suicide risk factors differ in depressed patients with concurrent SUD symptoms compared to those without SUD comorbidity...
  14. ncbi Divalproex in the treatment of bipolar depression: a placebo-controlled study
    Lori L Davis
    Veteran s Affairs Medical Center 151, 3701 Loop Road East, Tuscaloosa, AL 35404, USA
    J Affect Disord 85:259-66. 2005
    ..Thus, the potential antidepressant efficacy of mood stabilizers, such as divalproex, which is an effective treatment for the manic phase of bipolar disorder, is of considerable interest...
  15. ncbi A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study
    Lori L Davis
    VA Medical Center 151, 3701 Loop Road East, Tuscaloosa, AL 35404, USA
    J Clin Psychopharmacol 24:291-7. 2004
    ..06). This pilot study supports the efficacy of nefazodone for the treatment of PTSD. However, larger placebo-controlled studies in more diverse patient population are warranted...
  16. ncbi Baclofen treatment for chronic posttraumatic stress disorder
    Roger G Drake
    Clinical Pharmacy, Bryce Hospital, Tuscaloosa, AL, USA
    Ann Pharmacother 37:1177-81. 2003
    ..Larger, double-blind, placebo-controlled studies are needed to confirm the efficacy of baclofen in the treatment of PTSD...
  17. ncbi Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder
    Marshall E Cates
    McWhorter School of Pharmacy, Samford University, Birmingham, AL 35229 7027, USA
    Ann Pharmacother 38:1395-9. 2004
    ..Clonazepam is widely used for the treatment of posttraumatic stress disorder (PTSD)-related sleep disturbances despite very limited published data supporting its use for this indication...
  18. ncbi A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans
    Lori L Davis
    University of Alabama School of Medicine, Birmingham, AL, USA
    Psychopharmacol Bull 41:8-18. 2008
    ..This study tests the ability of the a(2) adrenergic agonist, guanfacine, to reduce the symptoms of PTSD...
  19. ncbi Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial
    Miles McFall
    Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, S 116 MHC, Seattle, WA 98108, USA
    JAMA 304:2485-93. 2010
    ..Most smokers with mental illness do not receive tobacco cessation treatment...
  20. ncbi Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder
    Xiaohua Li
    Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294 0017, USA
    Biol Psychiatry 61:216-22. 2007
    ..We tested whether lithium modified GSK3beta in vivo or in vitro in peripheral blood mononuclear cells (PBMCs) from healthy control and bipolar disorder subjects...
  21. ncbi Antidepressant medications, neuroleptics, and prominent eye movements during NREM sleep
    James D Geyer
    Neurology and Sleep Medicine, College of Community Health Sciences, The University of Alabama, Tuscaloosa, Alabama 35406, USA
    J Clin Neurophysiol 26:39-44. 2009
    ..Atypical NREM eye movements appear to be related primarily to serotonin and less prominently to dopaminergic medication effects...
  22. ncbi Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
    Arch Gen Psychiatry 65:870-80. 2008
    ..Little is known about selecting among second-step medications for major depressive disorder after intolerance or lack of remission with an initial selective serotonin reuptake inhibitor...
  23. ncbi Insured and non-insured depressed outpatients: how do they compare?
    Ira M Lesser
    Department of Psychiatry, Harbor UCLA Medical Center, The Los Angeles Biomedical Research Institute, Los Angeles, CA, USA
    Ann Clin Psychiatry 19:73-82. 2007
    ....
  24. ncbi Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial
    Brett A English
    Department of Pharmacology, Center for Molecular Neuroscience, Graduate Program in Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Clin Psychopharmacol 26:84-8. 2006
    ..Further study in a larger and more diverse patient sample is warranted prior to final conclusions on efficacy of citalopram for the treatment of PTSD...
  25. ncbi Characteristics of insured and noninsured outpatients with depression in STAR(*)D
    Ira M Lesser
    Harbor UCLA Medical Center, Box 8, 1000 West Carson Street, Torrance, California 90509, USA
    Psychiatr Serv 56:995-1004. 2005
    ....